A phase II evaluation of motesanib (AMG 706) in the treatment of persistent or recurrent ovarian, fallopian tube and primary peritoneal carcinomas: A Gynecologic Oncology Group study

Gynecologic Oncology

Volumn 129, Issue 1, 2013, Pages 86-91

  Schilder, R J ^a   Sill, M W ^b,c   Lankes, H A ^b   Gold, M A ^d   Mannel, R S ^d   Modesitt, S C ^e   Hanjani, P ^f   Bonebrake, A J ^g   Sood, A K ^h   Godwin, A K ⁱ   Hu, W ^h   Alpaugh, R K ^j  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c UNIVERSITY AT BUFFALO   (United States)

^d UNIVERSITY OF OKLAHOMA   (United States)

^e UNIVERSITY OF VIRGINIA   (United States)

^f ABINGTON MEMORIAL HOSPITAL   (United States)

^g Lester E Cox Medical Center   (United States)

^h UNIVERSITY OF TEXAS   (United States)

ⁱ UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^j FOX CHASE CANCER CENTER   (United States)

more..

Author keywords

Antiangiogenesis; Cancer; Encephalopathy; Motesanib; Ovarian

Indexed keywords

DNA; MOTESANIB; VASCULOTROPIN;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; BRAIN TOXICITY; CANCER INCIDENCE; CARCINOMATOUS PERITONITIS; CELL FREE SYSTEM; CEREBROVASCULAR ACCIDENT; CHOLECYSTITIS; CIRCULATING TUMOR CELL; CLINICAL ARTICLE; CONFUSION; CORRELATION ANALYSIS; DIARRHEA; DRUG EFFICACY; ENDOTHELIAL PROGENITOR CELL; ENDOTHELIUM CELL; FEMALE; HEADACHE; HUMAN; HYPERTENSION; HYPOCALCEMIA; HYPOPHOSPHATEMIA; NEPHROTOXICITY; OVARY CARCINOMA; PHASE 2 CLINICAL TRIAL; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PRIMARY TUMOR; PRIORITY JOURNAL; SEIZURE; TREATMENT RESPONSE; TUMOR RECURRENCE; UTERINE TUBE CARCINOMA; VISUAL DISORDER;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; DNA, NEOPLASM; FALLOPIAN TUBE NEOPLASMS; FEMALE; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; HUMANS; INDOLES; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NIACINAMIDE; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84875461329     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2013.01.006     Document Type: Article

References (42)

1. R. Siegel, D. Naishadham, and A. Jemal Cancer Statistics, 2012 CA Cancer J Clin 62 2012 10 29
2. R.F. Ozols, S.C. Rubin, G.M. Thomas, and S.J. Robboy W.J. Hoskins, C.A. Perez, R.C. Young, R.R. Barakat, M. Markman, M.E. Randall, Epithelial Ovarian Cancer in Principles and Practice of Gynecologic Oncology 2005 Lippincott Williams and Watkins Philadelphia, PA 895 989
3. L. Martin, and R. Schilder Novel approaches in advancing the treatment of epithelial ovarian cancer: the role of angiogenesis inhibition J Clin Oncol 10 25 2007 2894 2901
4. R.A. Burger, M.W. Sill, B.J. Monk, B.E. Greer, and J.I. Sorosky Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group study J Clin Oncol 25 2007 5165 5171
5. R.A. Burger, M.F. Brady, M.A. Bookman, G.F. Fleming, B.J. Monk, and H. Huang Incorporation of bevacizumab in the primary treatment of ovarian cancer N Engl J Med 365 2011 2473 2483
6. T. Perren, A.M. Swart, J. Pfisterer, J.A. Ledermann, E. Pujade-Lauraine, and G. Kristensen ICON7: a phase III of bevacizumab in ovarian cancer N Engl J Med 365 2011 2484 2496
7. F. Shojaei, and N. Ferrara Antiangiogenic therapy for cancer: an update Cancer J 13 2007 345 348
8. A. Polverino, A. Coxon, C. Starnes, Z. Diaz, T. DeMelfi, and L. Wang AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts Cancer Res 66 2006 8715 8721
9. L.S. Rosen, R. Kurzrock, M. Mulay, A. Van Vugt, M. Purdom, and C. Ng Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors J Clin Oncol 25 2007 2369 2376
10. Y. Fujisaka, Y. Yamada, N. Yamamoto, T. Shimizu, Y. Fujiwara, and K. Yamada Phase 1 study of the investigational, oral angiogenesis inhibitor motesanib in Japanese patients with advanced solid tumors Cancer Chemother Pharmacol 66 2010 935 943
11. S.I. Sherman, L.J. Wirth, J.-P. Droz, P.J. Droz, M. Hofmann, L. Bastholt, and R.G. Martins Motesanib diphosphate in progressive differentiated thyroid cancer N Engl J Med 359 2008 31 42
12. R.S. Benjamin, P. Schoffski, J.T. Hartmann, A. Van Oosterom, B.N. Bui, and J. Duyster Efficacy and safety of motesanib, an oral inhibitor of VEGF, PDGF, and Kit receptors, in patients with imatinib-resistant gastrointestinal stromal tumors Cancer Chemother Pharmacol 68 2011 69 77
13. M.J. Schlumberger, R. Ellsei, L. Bastholt, L.J. Wirth, R.G. Martins, and L.D. Locati Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer J Clin Oncol 27 2009 3794 3801
14. G.R. Blumenschein Jr., K. Reckamp, G.J. Stephenson, T. O'Rourke, G. Gladish, and J. McGreivy Phase 1b study of motesenib, an oral angiogenesis inhibitor, in combination with carboplatin/paclitaxel and/or panitumumab for the treatment of advanced non-small cell lung cancer Clin Cancer Res 16 2010 279 290
15. G.R. Blumenschein Jr., F. Kabbinavar, and H. Menon A phase II, multicenter, open-label randomized study of motesanib, or bevacizumab in combination with paclitaxel and carboplatin for non-small-cell lung cancer Ann Oncol 22 2011 2057 2067
16. G.V. Scaliotti, I. Vynnychenko, K. Park, Y. Ichinose, K. Kubota, and F. Blackhall International, randomized, placebo-controlled, double-blind phase III study of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous non-small-cell lung cancer: MONET1 J Clin Oncol 30 2012 2829 2836
17. P. Therasse, S.G. Arbuck, E.A. Eisenhauer, J. Wanders, R.S. Kaplan, and L. Rubinstein New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer. National Cancer Institute of Cancer J Natl Cancer Inst 92 2000 205 216
18. M.W. Sill, L. Rubinstein, S. Litwin, and G. Yothers A method for utilizing co-primary efficacy outcome measures to screen regimens for activity in two-stage Phase II clinical trials Clin Trials 9 2012 385 395
19. L. Usha, M.W. Sill, K.M. Darcy, D.M. Benbrook, J.A. Hurteau, and D.P. Michelin A Gynecologic Oncology Group phase II trial of the protein kinase C-beta inhibitor, enzastaurin and evaluation of markers with potential predictive and prognostic value in persistent or recurrent epithelial ovarian and primary peritoneal malignancies Gynecol Oncol 121 2011 455 461
20. C. Spearman The proof and measurement of association between two things Am J Psychol 15 1904 72 101
21. M. Hollander, and D.A. Wolfe Nonparametric statistical methods 1973 John Wiley & Sons New York
22. J.L. Hodges, and E.L. Lehmann Hodges-Lehmann Estimators S. Kotz, N.L. Johnson, C.B. Read, Encyclopedia of statistical sciences 1983 John Wiley & Sons New York 463 465
23. J. Hinchey, C. Chaves, B. Appignani, J. Breen, L. Pao, and A. Wang A reversible posterior leukoencephalopthy syndrome N Engl J Med 334 1996 494 500
24. M.A. Marinella, and R.J. Markert Reversible posterior leukoencephalopathy syndrome associated with anticancer drugs Intern Med J 39 2009 826 834
25. C. Vaughn, L. Zhang, and D. Schiff Reversible posterior leukoencephalopathy syndrome in cancer Curr Oncol Rep 10 2008 86 91
26. P. Glusker, L. Recht, and B. Lane Reversible posterior leukoencephalopathy syndrome and bevacizumab N Engl J Med 354 2006 980 982
27. C. Ozcan, S.J. Wong, and P. Hari Reversible posterior leukoencephalopathy syndrome and bevacizumab N Engl J Med 354 2006 980 982
28. A. Chen, and M. Agarwal Letters to the Editor. Clinical-scientific notes. Reversible posterior leukoencephalopathy syndrome associated with sunitinib Intern Med J 39 2009 341 345
29. R. Cumurciuc, L. Martinez-Almoyna, C. Henry, H. Husson H, and T. de Broucker Posterior reversible encephalopathy syndrome during sunitinib therapy Rev Neurol (Paris) 164 2008 605 607
30. R. Govindarajan, J. Adusumilli, D.L. Baxter, A. El-Khoueiry, and S.I. Harik Reversible posterior leukoencephalopathy syndrome induced by RAF kinase inhibitor BAY 43-9006 J Clin Oncol 24 2006 e48
31. C. Franjié, C. Lefaucheur, J. Medioni, C. Jacquot, G.S. Hill, and D. Nochy Renal thrombotic microangiopathy caused by anti-VEGF-antibody treatment for metastatic renal-cell carcinoma Lancet 8 2007 177 178
32. E. Kapiteijn, A. Brand, J. Kroep, and H. Gelderblom Sunitiib induced hypertension, thrombotic microangiopathy and reversible posterior leukencephalopathy syndrome Ann Oncol 18 2007 1745 1747
33. N.C. Tebbutt, D. Kotasek, H.A. Burris III, L.S. Schwartzberg, H. Hurwitz, and J. Stephenson Motesanib with or without panitumumab (pmab) plus FOLFIRI or FOLFOX for the treatment of metastatic colorectal cancer (mCRC) ASCO GI 2010 Ab # 416 2010 162 [Abstr]
34. P. Lorusso, E.I. Heath, J. McGreivy, Y.N. Sun, R. Melara, and L. Yan Effect of coadministration of ketoconazole, a strong CYP3A4 inhibitor, on pharmacokinetics and tolerability of motesanib diphosphate (AMG706) in patients with advanced solid tumors Invest New Drugs 26 2008 455 462
35. S. Monestiroli, P. Mancuso, A. Burlini, G. Pruneri, C. Dell'Agnola, and A. Gobbi Kinetics and viability of circulating endothelial cells as surrogate angiogenesis marker in an animal model of human lymphoma Cancer Res 61 2001 4341 4344
36. F. Bertolini, W. Mingrone, A. Alietti, P.F. Ferrucci, E. Cocorocchio, and F. Peccatori Thalidomide in multiple myeloma, myelodysplastic syndromes and histiocytosis. Analysis of clinical results and surrogate angiogenesis markers Ann Oncol 12 2001 987 990
37. A.A. Kamat, F.Z. Bischoff, D. Dang, M.F. Baldwin, L.Y. Han, and Y.G. Lin Circulating cell-free DNA: a novel biomarker for response to therapy in ovarian carcinoma Cancer Biol Ther 5 10 Oct 2006 1369 1374
38. S. Sawaki, Y. Yamasa, Y. Komatsu, T. Kanda, T. Doi, and M. Koseki Phase II study of motesanib in Japanese patients with advanced gastrointestinal stromal tumors with prior exposure to imatinib mesylate Cancer Chemother Pharmacol 65 2010 961 967
39. A. Coxon, J. Bready, J. Estrada, T. Osgood, J. Canon, and L. Wang Antitumor activity of motesanib in a medullary thyroid cancer model J Endocrinol Invest 35 2012 181 190
40. A. Tufro, J. Teichman, N. Banu, and G. Villegas Crosstalk between VEGF-A/VEGFR2 and GDNF/RET signaling pathways Biochem Biophys Res Commun 358 2007 410 416
41. G. Dole, E.E. Nilsson, and M.K. Skinner Glial-derived neurotrophic factor promotes ovarian primordial follicle development and cell-cell interaction during folliculogenesis Reproduction 135 2008 671 682
42. H. Koo, and B.H. Choi Expression of glial cell line-derived neurotrophic factor (GDNF) in the developing human fetal brain Int J Dev Neurosci 19 2001 549 558